QuidelOrtho Corporation

Transparency in Supply Chain Statement

for the Financial Year Ending 1 January 2023

1. Introduction

1.1 QuidelOrtho Corporation, a Delaware corporation ("QuidelOrtho"), is committed to preventing modern slavery and human trafficking in its business and supply chains, and those of its subsidiaries (together the "QuidelOrtho Group").

1.2 In accordance with its obligation under section 54 of the UK Modern Slavery Act 2015 (the "2015 Act"), QuidelOrtho sets out below a statement of the steps taken in the financial year ending 1 January, 2023 (the "Financial Year") to mitigate the risk of modern slavery and human trafficking from occurring in any part of the business or supply chains of QuidelOrtho.

1.3 This statement includes actions taken by Ortho-Clinical Diagnostics, a company incorporated under the laws of England and Wales ("Ortho UK"), a subsidiary of QuidelOrtho and member of the QuidelOrtho Group, and is also intended to fulfill Ortho UK's obligation to make a statement under the 2015 Act.

2. Our Business

2.1 QuidelOrtho's mission is to develop and manufacture intelligent diagnostic solutions that transform the power of diagnostics into a healthier future for everyone. Our expertise in point of care and molecular testing, clinical chemistry and transfusion medicine helps clinicians and patients make better informed decisions across the globe. Our global infrastructure and commercial reach support our customers in more than 130 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S. and U.K., and with sales centers, administrative offices and warehouses located across the globe.

2.2 On May 27, 2022, pursuant to a Business Combination Agreement entered into as of December 22, 2021, by and among Quidel Corporation ("Quidel"), Ortho Clinical Diagnostics Holdings plc ("Ortho"), QuidelOrtho and the other parties thereto, Quidel and Ortho consummated a business combination (the "Combinations") and each of Quidel and Ortho became a wholly owned subsidiary of QuidelOrtho.

2.3 QuidelOrtho's corporate headquarters is located in San Diego, California, U.S. Our primary manufacturing facilities are located in San Diego, California, Carlsbad, California, Athens, Ohio, Raritan, New Jersey, Rochester, New York, Pompano Beach, Florida and Pencoed, Wales.

2.4 As of January 1, 2023, we had approximately 7,000 employees worldwide, with approximately 4,200 employees in the U.S. and approximately 2,800 employees outside of the U.S. We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, retail clinics, pharmacies, wellness screening centers, other point-of-care settings, blood banks and donor centers, as well as for individual, non-professional, over-the-counter use.

3. Our Supply Chains

3.1 Due to the diverse nature of our manufactured products and markets, we have a complex and geographically broad range of suppliers of raw material, goods and services into our business.
3.2 Throughout the Financial Year, QuidelOrtho made concerted efforts to do business with diverse suppliers by incorporating diverse suppliers into its process of category reviews and product or service bids. Six categories of suppliers that QuidelOrtho considered to engage in business with are small businesses, small disadvantaged businesses, women-owned small businesses, veteran-owned small businesses, service disabled veteran-owned small businesses and HUBZone small businesses. Additionally, QuidelOrtho is an active member in the Women’s Business Enterprise National Council and National Minority Supplier Development Council.

4. Our Policies and Contractual Controls

4.1 QuidelOrtho Group promotes honest, ethical and lawful conduct throughout our business. Our Code of Business Conduct and Ethics (the “Code”) applied to all subsidiaries in the QuidelOrtho Group following the consummation of the Combinations and throughout the remainder of the Financial Year and is central to achieving these goals. Ethical behavior is the foundation to our success in achieving our business objectives and we recognize it is in our best interest to set standards for ourselves at all times in compliance with applicable laws, including not engaging in modern slavery or human trafficking, and to align ourselves with agents, representatives, suppliers and partners who have similar high standards of business conduct.

4.2 The Code applies to all directors, officers, employees, and temporary workers of the QuidelOrtho Group (“Company Employees”). The Code contains general guidelines for conducting the business of QuidelOrtho with integrity, honesty and business ethics in compliance with applicable laws and specifically prohibits human trafficking or any other forms of human rights abuses in our supply chain, facilities, or in carrying out our business. During the Financial Year, reported violations of the Code were investigated and appropriate actions were taken.

4.3 Ethical and lawful behavior is also a cornerstone of our dealings with service providers and suppliers. During the Financial Year, contract templates and terms and conditions set forth in purchase orders used by entities within the QuidelOrtho Group included obligations to comply with all applicable laws and regulations.

4.4 Under our Code, all Company Employees have a duty to report any known or suspected violation of the Code, including violations of the laws, rules, regulations or policies that apply to QuidelOrtho. During the Financial Year, we established the QuidelOrtho Ethics Hotline, which is available 24 hours a day, 7 days a week and is one method in which our Company Employees can raise concerns regarding modern slavery in our business or supply chains. Individuals may remain anonymous and will not be required to reveal their identities in the calls to the QuidelOrtho Ethics Hotline.

4.5 Adherence to and compliance with our policies and procedures, including the Code, mitigates the risks of modern slavery occurring in our business or supply chains.

5. Risk Assessment and Due Diligence

5.1 During the Financial Year, Ortho UK conducted third party due diligence, where appropriate, before contracting with potential suppliers, service providers, distributors and similar intermediaries. Preliminary risk assessments were performed by Ortho UK on potential suppliers with assessment questionnaires. Upon review of the questionnaires, as determined appropriate, Ortho UK could follow-up with an in-depth assessment conducted by either an internal supplier assessment team, or a third-party auditing firm.

---

1 Each of Quidel and Ortho adopted its own Code of Business Conduct and Ethics prior to the consummation of the Combinations. Effective May 27, 2022, QuidelOrtho’s Code replaced Quidel’s and Ortho’s respective policies.

2 Each of Quidel and Ortho maintained its own Ethics Hotline prior to the consummation of the Combinations. Effective May 27, 2022, QuidelOrtho’s Ethics Hotline replaced Quidel’s and Ortho’s respective Ethics Hotlines.
5.2 Following the Combinations and for the remainder of the Financial Year, QuidelOrtho adopted a Conflict Minerals Policy Statement, which established QuidelOrtho's commitment to complying with the Organisation for Economic Co-operation and Development Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas, as well as the applicable requirements of Section 1502 of the Dodd-Frank Act.

5.3 From time to time, the QuidelOrtho Group entities may conduct audits of direct material suppliers to evaluate supplier compliance with our standards, which includes compliance with applicable laws. Direct material suppliers may also be evaluated through audits on their compliance with the terms of our supply agreements. The audited may be conducted by either a QuidelOrtho supplier assessment team, or a third-party auditing firm. Following audits, suppliers may be required to produce a corrective action plan to outline how the supplier will resolve any issues uncovered in the audits.

5.4 During the Financial Year, we also conducted due diligence and right to work checks on our employees as appropriate to safeguard against human trafficking and forced labour.

5.5 During the Financial Year, no potential slavery or human trafficking issues within the business or supply chains of the QuidelOrtho Group were identified or reported through internal reporting channels or otherwise.

5.6 On this basis, given our policies and contractual controls detailed above, during the Financial Year, we believe the risk of slavery or human trafficking for QuidelOrtho Group in our business and its supply chain was low.

6. Approval of this statement

6.1 This statement was approved and signed by QuidelOrtho on September 27, 2023

Signed: ..........................
Douglas C. Bryant
President and Chief Executive Officer

---

3 Each of Quidel and Ortho adopted its own Conflict Minerals Policy Statements prior to the consummation of the Combinations. Effective May 27, 2022, QuidelOrtho's Conflict Minerals Policy Statement replaced Quidel's and Ortho's respective policy statements.